GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...
The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...
The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts.
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback